Pharmaceuticals
Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says
The newly FDA approved Alzheimer’s treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023. Hannah Yoon | The Washington Post | Getty Images The breakthrough Alzheimer’s drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term, […]
Read More
Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs
Kena Betancur | Corbis News | Getty Images Pfizer on Thursday reported second-quarter revenue and adjusted earnings that blew past expectations and raised its full-year outlook, benefiting from its broad cost-cutting program, better-than-expected sales of its Covid antiviral pill Paxlovid and strong non-Covid product sales. The company now expects to book adjusted earnings of $2.45 to $2.65 […]
Read More
Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says
A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer’s disease by protecting patients’ brains, according to data […]
Read More
Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024. Spencer Platt | Getty Images Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology […]
Read More
Jim Cramer’s advice on Abbott Labs stock after a nearly $500 million baby formula verdict
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. Wall Street was lower after Friday’s rebound in a wild week that featured rotations in and out of tech. It’s a busy week ahead with a Fed meeting, 14 earnings […]
Read More
FDA approves new blood test to screen for colon cancer
The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer. The test isn’t meant to replace colonoscopies, but is generating enthusiasm among doctors who say it has the potential to boost the dismal rate of screenings for the second-highest cause of cancer death in the United States. Shield […]
Read More
Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data
Sopa Images | Lightrocket | Getty Images Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company’s two obesity drug candidates are progressing to the next phase of trials and could come to market within the next few years, […]
Read More
Italy’s Meloni vows to ‘relaunch’ cooperation with China
Italy and China flag together realtions textile cloth fabric texture Oleksii Liskonih | Istock | Getty Images Italian Prime Minister Giorgia Meloni vowed on Sunday to “relaunch” cooperation with China, signing a three-year action plan during her first official visit to Beijing since taking office. Meloni, who has led a right-wing government since 2022, made the announcement during a meeting with Chinese […]
Read More
European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The European Commission, the EU’s executive body, has a final say in Leqembi’s approval. But it almost always follows the drug regulator’s recommendations. […]
Read More
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Friday reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance as the drugmaker moves to slash costs. The pharmaceutical giant raised its […]
Read More